Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

Author:

Eto Shohei,Nukui Yoko,Tsumura Miyuki,Nakagama Yu,Kashimada Kenichi,Mizoguchi Yoko,Utsumi Takanori,Taniguchi Maki,Sakura Fumiaki,Noma Kosuke,Yoshida Yusuke,Ohshimo Shinichiro,Nagashima Shintaro,Okamoto Keisuke,Endo Akifumi,Imai Kohsuke,Kanegane Hirokazu,Ohnishi Hidenori,Hirata Shintaro,Sugiyama Eiji,Shime Nobuaki,Ito Masanori,Ohge Hiroki,Kido Yasutoshi,Bastard Paul,Casanova Jean-Laurent,Ohara Osamu,Tanaka Junko,Morio Tomohiro,Okada SatoshiORCID

Funder

Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Osaka City University Strategic Research Grant

National Institutes of Health

National Center for Advancing Translational Sciences

the French National Research Agency

the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence

the French Foundation for Medical Research

ANR GENVIR

ANR AABIFNCOV

ANR GenMISC

the European Union’s Horizon 2020 research and innovation programme under grant agreement

The French Ministry of Higher Education, Research, and Innovation

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3